Assess immunogenicity, safety % reactogenicity of a 4th dose of GSK Biologicals’ Tritanrix™-HepB/Hib-MenAC at 15-24 months % of a dose of Mencevax™ ACWY at 24-30 months in subjects primed with 3 doses of Tritanrix™-HepB/Hib-MenAC
Combined Diphtheria, Tetanus, Whole Cell Pertussis, Hepatitis B, Haemophilus influenzae Type b Vaccine
Diphtheria; Haemophilus influenzae type b; Hepatitis B; Tetanus; Whole Cell Pertussis
Phase 3
An annotated case report form is not available for this study. A blank case report form will be provided.
October 2014